Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

Abstract

Liraglutide treatment for 8 weeks did not significantly change PASI, DLQI, or hsCRP in a small group of glucose-tolerant obese patients with plaque psoriasis compared with placebo. A significant weight loss and decrease in cholesterol levels was observed in liraglutide-treated patients.